Tracking Blood Eosinophil Levels in Severe COPD Flare-Ups
Studies low eosinophil counts and recovery in adults hospitalized for severe COPD flare-ups.
Plain-language title generated from the registry record
Registry title: Eosinopenia in Severe COPD Exacerbation
Key facts
- Where
- North Shields, United KingdomSee the site
Where in United Kingdom
- Northumbria Healthcare NHS Foundation TrustNorth Shields, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northumbria Healthcare NHS Foundation Trust
- Trial code
- NCT06188065
- Record updated
- 14 April 2026
- Original description
The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia.Read full original descriptionShow less
Associates of, and Time to Recovery From, Eosinopenia in Severe COPD Exacerbation
The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia.
The main aims of the study are to:
1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD 2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD
Inclusion: Admitted to hospital with primary clinical diagnosis of exacerbation of COPD*; Smoking history of at least 10 pack years; Airflow obstruction: FEV1/FVC ratio < 0.7 confirmed on historic or inpatient spirometry; Capacity to give informed consent to participate; Eosinopenia on admission; Uneventful recovery*; Eosinopenia on admission who do not receive a further course of systemic corticosteroids or require emergency hospital admission for an acute illness in the six weeks following admission to hospital with a severe exacerbation of COPD.
Exclusion: Maintenance oral prednisolone or other systemic steroids, anti-interleukin 5 therapy or other medication known to influence eosinophils; Active malignancy; Investigator confirmed history of asthma; Parasitic infection, systemic fungal infection (excluding infection limited to nails or skin), eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome or other conditions associated with a high eosinophil count#; Patients with poor venous access; Non-COPD related health problems which in the view of the primary investigator may compromise the conduct and completion of the study; ADDITIONAL CRITERIA FOR THE TIME TO RECOVERY FROM EOSINOPENIA ANALYSIS ONLY.